Skip to main content

Table 1 Statistical power (1-β) of a trial comparing nitric oxide with placebo (n = 90 patients per group) for the adjunctive therapy of severe malaria, using longitudinal Ang-2 levels as primary outcome

From: Inhaled nitric oxide for the adjunctive therapy of severe malaria: Protocol for a randomized controlled trial

Standard Deviation of Ang-2 levels at admission (% of mean)

Difference in rate of change of Ang-2 between groups

 

30% change (810 pg/mL/day)

40% change (1080 pg/mL/day)

50% change (1350 pg/mL/day)

40

82%

97%

99%

50

66%

89%

98%

80

42%

60%

80%